Contains Natural Gums And Resins Patents (Class 424/500)
-
Patent number: 6440462Abstract: Agglomerates of &bgr;-lactam antibiotics, such as penicilllin V potassium, amoxicillin trihydrate, cephalexin monohydrate, which are suitable for direct tablet formation.Type: GrantFiled: September 2, 1998Date of Patent: August 27, 2002Assignee: Biochemie Gesellschaft m.b.H.Inventors: Johannes Raneburger, Erich Zeisl
-
Patent number: 6426077Abstract: A wholesome food product with many uses, for weight control, health and nutrition.Type: GrantFiled: August 4, 2000Date of Patent: July 30, 2002Assignee: Indoor Tennis Consultants, Inc.Inventors: Margery Grace, Rena Northrop, Joyce Kiley
-
Publication number: 20020090395Abstract: An oral pharmaceutical dosage form including a mixture of a delay release formulation of a non-steroidal anti-inflammatory drug (NSAID) and a mixture containing a prostaglandin and one or more excipients.Type: ApplicationFiled: October 7, 1999Publication date: July 11, 2002Inventors: AUSTEN JOHN WOOLFE, SIOBHAN GREENE, GORDON MCINTYRE
-
Patent number: 6406703Abstract: The application discloses a method for the treatment of Heliobacter infection in a mammalian host, which comprises administration to said infected host of an immunologically effective amount of one or more Heliobacter antigen(s), optionally in association with a mucosal adjuvant.Type: GrantFiled: July 5, 2000Date of Patent: June 18, 2002Assignees: CSL Limited, The University of New South WalesInventors: Christopher Vincent Doidge, Adrian Lee
-
Publication number: 20020058070Abstract: A masking agent for pharmaceutical tastes comprises a mixture of a sapid agent and an enhancer, in the form of an intimate mixture. The sapid agent/enhancer distribution is substantially homogeneous and non-statistical. The proportion of sapid agent relative to the enhancer is substantially constant and equal in all powder particles. The masking agent can have a grain size comprised between 10 and 100 &mgr;um, with a Gaussian distribution. The proportion of sapid agent/enhancer is comprised between 97/3 and 90/10, expressed in parts by weight. The sapid agent comprises a sweetener selected from the group comprising sodium saccharinates, calcium saccharinates, saccharine, aspartyl-phenylalanine, acesulfam, cyclamates, stevioside, and mixtures thereof; and the enhancer is selected from the group comprising thaumatin, neohesperidin dihydrochalcone (NHDC), glycyrrhizin, and mixtures thereof. A method of producing a masking agent is also disclosed.Type: ApplicationFiled: October 24, 2001Publication date: May 16, 2002Inventors: Denis Felisaz, Yvan Jacquier
-
Patent number: 6387398Abstract: Cosmetic or pharmaceutical formulations such as (a) anhydrous cosmetic stick formulations and (b) anhydrous aerosol spray formulations, comprising an organic dispersion medium having particles dispersed therein, which particles are preferably prepared by a process comprising spray-drying a mixture of liposome encapsulated active agent, modified starch, and optionally a hydrocolloid gum such as maltodextrin.Type: GrantFiled: August 2, 1999Date of Patent: May 14, 2002Assignee: Dragoco Gerberding & Co. AGInventors: Jürgen Vollhardt, Nisha Malkan, Robert P. Manzo
-
Patent number: 6387394Abstract: Controlled release powder insufflation formulations are disclosed. The powder formulation includes cohesive composites of particles containing a medicament and a controlled release carrier which preferably includes one or more polysaccharide gums of natural origin.Type: GrantFiled: July 26, 1999Date of Patent: May 14, 2002Assignee: Penwest Pharmaceuticals Co.Inventors: Anand Baichwal, John N. Staniforth
-
Patent number: 6379707Abstract: A formulation of a sparingly water-soluble, crystalline pharmaceutically active agent wherein the active agent is converted to and stabilized in its amorphous form as a solid solution of a normally hydrophobic vehicle is described. The amorphous state is stabilized by the composition of the formulation, providing long shelf life of the improved composition. This stabilized formulation also provides increased solubility and bioavailability of the active agent. Solutions of the active agent are stabilized by the composition, preventing recrystallization and precipitation of the less soluble, crystalline form of the active agent from aqueous solutions thereof.Type: GrantFiled: June 21, 2001Date of Patent: April 30, 2002Assignee: FMC CorporationInventors: Ronald S. Vladyka, Jr., David F. Erkoboni, Pamela R. Stergios
-
Patent number: 6369043Abstract: An sodium ion absorption inhibitor, a sodium ion excretion accelerator and an agent for preventing and treating a disease caused by excessive common salt ingestion, each of which comprising a metal salt (excluding sodium salt) of lambda-carrageenan as an active ingredient, can excrete excessively ingested common salt outside the body positively and safely, and particularly have excellent action in excreting the sodium ions into feces.Type: GrantFiled: June 26, 2000Date of Patent: April 9, 2002Assignee: Otsuka Pharmaceutical Factory, Inc.Inventors: Takaya Sato, Tutomu Uehara, Ippei Yamaoka, Kozo Asagi, Masaru Kobayashi, Hideaki Kohri
-
Patent number: 6365189Abstract: A microbead having a matrix core comprising a hydrophilic matrix and droplets of active material entrained therein, and a secondary layer adjacent to the outer surface of the matrix core. The secondary layer may be ionically complexed or hydrogen bonded to the matrix core surface. Compositions comprising the microbeads suspended in solution may be sprayable. The microbeads of the invention may be controllable by exposing the microbeads to high or low humidity or moisture.Type: GrantFiled: October 22, 1999Date of Patent: April 2, 2002Assignee: 3M Innovative Properties CompanyInventor: Douglas Quong
-
Publication number: 20020034474Abstract: A composition and method of fabrication are presented with which nanoparticles may be used as a tool to deliver drugs to a specific target within or on a mammalian body Specifically, by using stabilizers other than Dextran 70.000 during the polymerization process, according to the present invention, surfactants, which were deemed necessary coating material in the prior art, are no longer required. This is a significant simplification of the fabrication procedure. Many substances are useful as stabilizers, but the preferred stabilizers comprise Dextran 12.000 or polysorbate 85. In the present invention a drug is either incorporated into or adsorbed onto the stabilized nanoparticles. This drug/nanoparticle complex is then administered to the organism on any route such as by oral application, injection or inhalation, whereupon the drug exerts its effect at the desired site of pharmacological action.Type: ApplicationFiled: February 23, 2000Publication date: March 21, 2002Inventors: BERNHARD A. SABEL, ULRIKE SCHROEDER
-
Patent number: 6348217Abstract: A stable bleached shellac and an improved method for making stable bleached shellac is provided which involves precipitating bleached stable shellac from a pre-shellac solution at a pH of from 5.0 to 6.8, preferably from 5.0 to 6.5, most preferably from 5.0 to 6.0. The stable particulate shellac and the stable shellac solution, have a longer shelf life than conventional shellac. The stable shellac solution is comprised of solubilized particulate shellac in a solvent, most preferably ethanol. The stable particulate shellac and the stable shellac solution have a pH of from 4 up to less than 5 or from 5.0 to 6.8, more preferably from 5.0 to 6.5, even more preferably from 5.0 to 6.3, most preferably from 5.0 to 6.0.Type: GrantFiled: August 4, 2000Date of Patent: February 19, 2002Assignee: Mantrose-Haeuser Co. Inc.Inventors: Stephen A. Santos, Joseph F. Cotter, Sr., Margaret M. McWeeney
-
Publication number: 20010046973Abstract: Contact lens care compositions for the treatment of hard contact lenses are disclosed. The compositions are useful for rinsing, cleaning, disinfecting and storing of hard contact lenses. The compositions contain an unique gelling system involving galactomannan polysaccharides and borates to allow for the conditioning of the lens when it is reinserted in the eye of the user. Methods of using these compositions are also disclosed.Type: ApplicationFiled: June 18, 2001Publication date: November 29, 2001Inventor: Bahram Asgharian
-
Patent number: 6296873Abstract: A zero-order sustained-release delivery system for delivery of carbamazepine or a derivative thereof. A polymeric matrix formulation of carbamazepine comprises hydrophilic polymer or hydrophilic/hydropholic polymer mixture which permits carbamazepine or carbamezepine derivative to be released from the polymer matrix in zero-order release kinetics.Type: GrantFiled: March 31, 2000Date of Patent: October 2, 2001Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Ifat Katzhendler, Michael Friedman
-
Patent number: 6290991Abstract: The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass loaded with the bioactive material and capable of releasing the bioactive material in situ. The present invention further includes methods of making and using the solid dose delivery vehicle of the invention.Type: GrantFiled: December 2, 1994Date of Patent: September 18, 2001Assignee: Quandrant Holdings Cambridge LimitedInventors: Bruce J. Roser, Jaap Kampinga, Camilo Colaco, Julian Blair
-
Publication number: 20010016577Abstract: The present invention relates to mucoadhesive compositions comprising a safe and effective amount of a gastrointestinal active; from about 1.5% to about 10%, by weight of the composition, of a clay component; and from about 0.01% to about 1%, by weight of the composition, of a gum component. Alternatively, the clay component can be a titanium dioxide or a silicone dioxide component. The mucoadhesive compositions also preferably comprise up to about 2% by weight of the composition, of a non-ionic component such as methyl cellulose. The present invention also relates to methods of prevention and treatment of gastrointestinal tract disorders in humans or lower animals by orally administering a composition of the present invention.Type: ApplicationFiled: July 27, 1999Publication date: August 23, 2001Inventors: DOUGLAS JOSEPH DOBROZSI, TODD EHREN VIENNEAU, CHRISTOPHER ROBERT MAYER, KISHORKUMAR JIVANLAL DESAL
-
Publication number: 20010006681Abstract: The invention relates to therapeutic compositions and methods for treating and preventing infection by an immunodeficiency virus, particularly HIV infection, using chemokine proteins, nucleic acids and/or derivatives or analogs thereof.Type: ApplicationFiled: December 22, 2000Publication date: July 5, 2001Inventors: Anthony De Vico, Alfredo Garzino-Demo, Robert C. Gallo
-
Patent number: 6254893Abstract: A calcium-based ophthalmic composition for treating dry eye including a hydrophobic carrier, such as petrolatum, and a calcium salt. Also a method for treating dry eye comprising the step of administering the composition according to the present invention.Type: GrantFiled: October 23, 1998Date of Patent: July 3, 2001Assignee: DEO CorporationInventor: Donald L. MacKeen
-
Patent number: 6221399Abstract: A method of making a solid interpolymer for use as a controlled release matrix for a controlled release product for oral administration, involves dissolving a first polymer in a solvent therefor, dissolving one or more second complementary polymers capable of complexing with the first polymer to form the interpolymer complex, in a solvent therefor, adding a complexation inhibitor, mixing together the solutions, adjusting the pH if necessary, and spraying the product into a vessel to remove at least partially the solvents and thereby to produce solid particles of the interpolymer complex. An active agent such as a drug is preferably embedded or encapsulated in the interpolymer complex before spray drying or may be incorporated by suitable means at a later stage.Type: GrantFiled: June 1, 1998Date of Patent: April 24, 2001Assignee: CSIRInventors: Heidi Rolfes, Thilo Lothar Van Der Merwe, Patricia-Ann Truter
-
Patent number: 6197350Abstract: A method of producing sustained-release microcapsules which comprises dispersing a physiologically active polypeptide into a solution of a biodegradable polymer and zinc oxide in an organic solvent, followed by removing the organic solvent; which provides a sustained-release preparation showing a high entrapment ratio of the physiologically active polypeptide and its constant high blood concentration levels over a long period of time.Type: GrantFiled: May 27, 1999Date of Patent: March 6, 2001Assignee: Takeda Chemical Industries, Ltd.Inventors: Yutaka Yamagata, Masafumi Misaki, Susumu Iwasa
-
Patent number: 6180099Abstract: A composition for restoring and maintaining gastrointestinal health comprises 40-60% by weight of an immunoglobulin composition comprising concentrated immunologically active immunoglobulins and 40-60% by weight of soluble dietary fiber selected from inulin, fructo-oligosaccharides, pectin, guar gum, and mixtures thereof. The immunoglobulin and fiber-containing composition can optionally contain one or more of a beneficial human intestinal microorganism, components of a non-immune natural defense system, an iron-sequestering molecule, and gluconic acid. Preferred beneficial human intestinal microorganisms include lactobacilli and bifidobacteria. The immunologically active immunoglobulins are preferably purified from bovine milk, milk products, or whey. Methods of use are also described.Type: GrantFiled: April 17, 1998Date of Patent: January 30, 2001Assignee: Metagenics, Inc.Inventor: Stephen M. Paul
-
Patent number: 6156339Abstract: This invention relates to a process for the preparation of an oral solid rapidly disintegrating dosage form of a pharmaceutically active substance which has an unacceptable taste which process comprises: (i) forming a solution or a suspension in a solvent of a water soluble or water dispersible carrier, a filler and the pharmaceutically active substance with the unacceptable taste in association with a lipid, the weight ratio of the pharmaceutically active substance to the lipid being in the range of from 1:1 to 1:10 and the weight ratio of the carrier to the lipid being in the range of from 5:1 to 1:15; (ii) forming discrete units of the suspension or solution; and (iii) removing the solvent from the discrete units under conditions whereby unit dosages are formed comprising a network of carrier/filler carrying a dosage of the pharmaceutically active substance in association with the lipid; oral solid rapidly disintegrating dosage forms prepared by such a process are also provided.Type: GrantFiled: August 10, 1999Date of Patent: December 5, 2000Assignee: R.P. Scherer CorporationInventors: Leon Grother, Michael Hall, Douglas Bryans, Richard Green, Patrick Kearney
-
Patent number: 6120805Abstract: Biocompatible microspheres containing one or more active principals, a biodegradable and biocompatible polymer and a surface-active agent which is also biodegradable and biocompatible, contain less than 10 ppm of heavy metals. These microspheres are prepared by providing a solution of the polymer and of the active principal in a water-immiscible solvent which is more volatile than water and mixing with an aqueous solution of the surface-active agent, followed by evaporation of the solvent.Type: GrantFiled: May 31, 1995Date of Patent: September 19, 2000Assignee: Rhone-Poulenc Rorer SAInventors: Gilles Spenlehauer, Michel Veillard, Thierry Verrechia
-
Patent number: 6110502Abstract: A method for preparing .beta.-sitosterol is disclosed which provides the sterol in a readily consumable form. The method includes the spray drying of the .beta.-sitosterol in a mixed micelle formulation. The product is provided in a convenient form that can be provided to food or drinks or incorporated into solid and suspension dosage forms.Type: GrantFiled: February 19, 1998Date of Patent: August 29, 2000Assignee: McNeil-PPC, Inc.Inventors: Brid Burruano, Richard D. Bruce, Michael R. Hoy
-
Patent number: 6103251Abstract: A process for the administration of a flowable solid, semisolid, or liquid medium exhibiting a controlled release of at least one active substance to plants by means of injection using needle-free, pressure-actuated devices is characterized in that the medium comprises active substance-containing microparticles of a maximum size of 100 .mu.m including the following components:a) 0.5-70%-wt. of at least one active substance,b) 10-70%-wt. of at least one biodegradable polymer,c) up to 20%-wt. of formulation adjuvants.Type: GrantFiled: September 14, 1998Date of Patent: August 15, 2000Assignee: LTS Lohmann Therapie-Systeme GmbHInventors: Hans-Rainer Hoffmann, Malgorzata Kloczko, Michael Roreger
-
Patent number: 6096344Abstract: A composition for the sequestration and sustained delivery of an active ingredient in the form of porous particles, the composition comprising the product of the controlled dehydration of particles formed by the reaction of a polymeric anionic material with a polyvalent cation. The composition may be loaded with an active ingredient by soaking the particles in a solution of the active ingredient; and may then be dehydrated. They may then be soaked in a solution of a polymeric cationic material, to form particles providing the controlled release of the active ingredient.Type: GrantFiled: February 24, 1997Date of Patent: August 1, 2000Assignee: Advanced Polymer Systems, Inc.Inventors: Lin-Shu Liu, Michael Froix, Jorge Heller, Steven Y. Ng
-
Patent number: 6083529Abstract: A stable dry powder skin care powder having prolonged and controlled release properties, useful as baby powders, body talcs, deodorizing powders, OTC eczema preparations, foot powders, anti-fungal powders, etc. The dry powder is preferably prepared by a process comprising spray-drying a mixture of liposome encapsulated active agent, starch and maltodextrin. The particle is designed so that activity of, e.g., an anti-inflammatory agent such as Dragosantol.RTM. can be specifically triggered by skin conditions, such as moisture, for optimal timing of delivery.Type: GrantFiled: April 13, 1998Date of Patent: July 4, 2000Assignee: Dragoco Gerberding & Co. AGInventors: Robert P. Manzo, Jurgen Vollhardt, Nisha Malkan, Gary Friars
-
Patent number: 6056974Abstract: The present invention provides a rapid-release tablet of S1452 at least containing the following components:a. a principal agent comprising (+)-(Z)-calcium 7-[(1R,2S,3S,4S)-3-benzenesulfonaidobicyclo[2.2.1]hept-2-yl]-5-heptenoate dihydrate (S1452), andb. a dispersant in an amount enough to disperse the principal agent after the disintegration of the tablet.Type: GrantFiled: August 12, 1998Date of Patent: May 2, 2000Assignee: Shionogi & Co., Ltd.Inventors: Eizo Wakamiya, Yoshikazu Suzuki, Hitoshi Kadota
-
Patent number: 6056977Abstract: This invention is directed to a novel solid matrixed controlled release, oral dosage form where the dosage form contains a therapeutically effective amount of a sulfonylurea or a salt or derivative thereof in the matrix. Further, the use of an aqueous alkalizing medium affords substantially complete bioavailability of the drug from the matrix of the tablet. The core tablets may optionally be coated with a coating material in the range of 2% to 10% with an enteric material or with a water insoluble material like ethyl cellulose.Type: GrantFiled: October 15, 1997Date of Patent: May 2, 2000Assignee: Edward Mendell Co., Inc.Inventors: Dileep Bhagwat, Donald Diehl, II, Anand R. Baichwal
-
Patent number: 6051259Abstract: The method of the invention for producing a composition for the sustained release of biologically active hGH includes dissolving a biocompatible polymer in a polymer solvent to form a polymer solution, dispersing particles of biologically active, metal cation-stabilized hGH in the polymer solution, and then solidifying the polymer to form a polymeric matrix containing a dispersion of said hGH particles.Type: GrantFiled: February 19, 1999Date of Patent: April 18, 2000Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: OluFunmi Lily Johnson, Medha M. Ganmukhi, Howard Bernstein, Henry Auer, M. Amin Khan
-
Patent number: 6039980Abstract: A sustained-release formulation for use in oral solid dosage forms includes from about 10 to about 40 percent or more by weight galactomannan gum; from about 1 to about 20 percent by weight of an ionizable gel strength enhancing agent and an inert pharmaceutical filler.Type: GrantFiled: July 29, 1998Date of Patent: March 21, 2000Assignee: Edward Mendell Co., Inc.Inventor: Anand R. Baichwal
-
Patent number: 6022563Abstract: A powdered carrier formulation for delivery of phenylbutazone to animals contains phenylbutazone in combination with a flavoring agent and an anticaking agent.Type: GrantFiled: February 1, 1999Date of Patent: February 8, 2000Assignee: Superior Equine Pharmaceuticals, Inc.Inventor: Douglas J. Gordon
-
Patent number: 5997907Abstract: Methods for enhancing the stability of thickening agent solutions, especially guar solutions, by sterilizing the solution with UV light and/or adding a surfactant to the solution are disclosed. Thickening agent solutions and powders, including guar solutions and powders, as well as products made from these solutions and powders, are also disclosed.Type: GrantFiled: December 19, 1997Date of Patent: December 7, 1999Assignee: Rhodia Inc.Inventors: Animesh Goswami, Paul-Joel Derian
-
Patent number: 5993860Abstract: An oral-delivery pharmaceutical composition for reducing the gastric irritation effect of an NSAID in the upper GI tract of a mammal. The composition includes (a) a mucosal protective amount of a pharmaceutically-acceptable hydrocolloid gum obtainable from higher plants, (b) a dispersion-enhancing amount of another excipient and (c) a therapeutically-effective amount of an NSAID. Also disclosed is a process for preparing the composition and a method for reducing the gastric irritation effect of the NSAID by administering the composition. Also, disclosed is a composition particularly useful for preparing an aqueous suspension.Type: GrantFiled: November 13, 1997Date of Patent: November 30, 1999Assignee: Venture LendingInventors: Eric H. Kuhrts, David R. Friend, Karen Yu, Jagdish Parasrampuria
-
Patent number: 5980942Abstract: A zero-order sustained-release delivery system for delivery of carbamazepine. A matrix tablet formulations of carbamazepine comprising hydrophilic polymer gel which inhibits transformation of carbamazepine into carbamazepine dihydrate by causing morphologic changes of carbamazepine crystals and results in amorphous form of carbamazepine present in the polymer matrix.Type: GrantFiled: January 23, 1998Date of Patent: November 9, 1999Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Ifat Katzhendler, Michael Friedman
-
Patent number: 5962009Abstract: Controlled release powder insufflation formulations are disclosed. The powder formulation includes cohesive composites of particles containing a medicament and a controlled release carrier which preferably includes one or more polysaccharide gums of natural origin.Type: GrantFiled: December 30, 1996Date of Patent: October 5, 1999Assignee: Edward Mendell Co., Inc.Inventors: Anand Baichwal, John N. Staniforth
-
Patent number: 5952007Abstract: The use of complex coacervates of two or more biopolymer materials, preferably at least one of these being gelatin, as a fat-replacing ingredient. The complex coacervates may be used in foods and cosmetics and preferably are of substantially spherical or elliptical shape and have an average D.sub.3,2 particle size, of from 0.2 to 100 microns.Type: GrantFiled: April 10, 1996Date of Patent: September 14, 1999Assignee: Van den Bergh Foods Co.Inventors: Marinus Adriaan Bakker, Mettina Maria Koning, Johannes Visser
-
Patent number: 5919408Abstract: The invention relates to a process for the production of pseudolatices or micro- and/or nanoparticles, in which a polymer is crystalline, partially crystalline or amorphous, is selected from cellulose derivatives, poly(meth)acrylates, shellac, polylactides, polylactide/polyglycolide mixtures, polyhydroxy butyric acids or polycyanoacrylates and is heated to a temperature above its glass transition temperature and then high-pressure homogenized in water or an aqueous buffer solution and this suspension is converted, if necessary, into micro- and/or nanoparticles by drying. Medicaments can be worked into the pseudolatices, micro- and/or nanoparticles.Type: GrantFiled: September 20, 1995Date of Patent: July 6, 1999Assignee: Pharmatech GmbHInventors: Bernd W. Muller, Felix Junis-Specht
-
Patent number: 5891478Abstract: The method of the invention for producing a composition for the sustained release of biologically active hGH includes dissolving a biocompatible polymer in a polymer solvent to form a polymer solution, dispersing particles of biologically active, metal cation-stabilized hGH in the polymer solution, and then solidifying the polymer to form a polymeric matrix containing a dispersion of said hGH particles.Type: GrantFiled: March 2, 1998Date of Patent: April 6, 1999Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: OluFunmi Lily Johnson, Medha M. Ganmukhi, Howard Bernstein, Henry Auer, M. Amin Khan
-
Patent number: 5885603Abstract: This invention relates to novel biopesticidal compositions comprising an active insecticidal ingredient selected from insecticidal bacteria and viruses such as B. thuringiensis crystal protein or spores or mixtures thereof and baculoviruses such as nuclear polyhedrosis viruses, granulosis viruses and non-occluded viruses; a polymer; and an inorganic light blocking agent wherein the light blocking agent protects the active ingredient from both ultraviolet light and sunlight and the polymer forms a matrix in which the active ingredient and light blocking agent are dispersed therein. Methods for producing the biopesticidal compositions and methods of controlling insects are also included within the scope of the invention.Type: GrantFiled: August 7, 1997Date of Patent: March 23, 1999Assignee: Novartis CorporationInventors: Jeffrey D. Fowler, Benjamin E. Feinstein
-
Patent number: 5874096Abstract: Aerial spray or discharge drift is controlled in aqueous compositions via the use of selected non-visco-elastic amounts of guar, one or more derivatives of guar, or combinations thereof.Type: GrantFiled: August 26, 1996Date of Patent: February 23, 1999Assignee: Rhodia Inc.Inventor: James Lyle Hazen
-
Patent number: 5863554Abstract: A drug delivery system including a plurality of microsphere particles containing an active drug and including a material associated with each particle which material has the property of increasing the bioavailability of the active drug.Type: GrantFiled: July 24, 1997Date of Patent: January 26, 1999Assignee: Danbiosyst UK LimitedInventor: Lisbeth Illum
-
Patent number: 5830508Abstract: A calcium-based ophthalmic composition for treating dry eye is disclosed. The composition includes a hydrophobic carrier such as petrolatum and a calcium salt. The composition can further include a polyol such as glycerol, and an agent such as anhydrous lanolin, to enhance the interface between the carrier, and the calcium salt and polyol. Also disclosed is a method for treating dry eye comprising the step of administering the composition according to the present invention by placing the composition on the lateral portion of the lower eyelid margin. This method allows the composition to gradually disperse onto the cornea and conjunctiva.Type: GrantFiled: January 21, 1997Date of Patent: November 3, 1998Assignee: Deo CorporationInventor: Donald L. MacKeen
-
Patent number: 5814341Abstract: A cosmetic composition is provided comprising:A) a cosmetically acceptable carrier; andB) 0.05 to 3.0% by weight, based on the weight of the total composition, of a .beta.-1,3-glucan having a mean molecular weight of 10.sup.5 to 25.10.sup.6.Type: GrantFiled: August 12, 1996Date of Patent: September 29, 1998Assignee: Ciba Specialty Chemicals CorporationInventors: Peter Fankhauser, Thomas Maier
-
Patent number: 5811124Abstract: An microparticle composition and its method of use in drug delivery and diagnostic applications are disclosed. Also disclosed are methods of storing and administering drug compounds at high concentration in condensed-phase microparticles.Type: GrantFiled: February 15, 1995Date of Patent: September 22, 1998Assignee: Mayo Foundation for Medical Education and ResearchInventors: Julio M. Fernandez, Mark B. Knudson
-
Patent number: 5804212Abstract: A drug delivery composition for intranasal delivery comprises a plurality of bioadhesive microspheres and active drug associated with each microsphere, at least 90 wt % of the microspheres having a diameter in the range 0.1 .mu.m to 10 .mu.m. The microspheres may be of starch, gelatin, dextran, collagen or albumin. Suitable drugs include peptides, such as insulin, and antigenic vaccine ingredients. The composition may additionally comprise an absorption enhancer. The microspheres are administered to the nasal cavity by a means such that the product of the square of the microsphere diameter and the flow rate is greater than 2000 .mu.m.sup.2.liters/min.Type: GrantFiled: June 17, 1997Date of Patent: September 8, 1998Assignee: Danbiosyst UK LimitedInventor: Lisbeth Illum
-
Patent number: 5795585Abstract: A ruminant feed additive composition comprises a phosphoric acid-amino acid composite salt and a water-insoluble salt of a polyvalent-metal-sensitive water-soluble high-molecular weight substance. The composite salt contains a basic amino acid, an alkaline-earth metal and phosphoric acid, and is insoluble in neutral or alkaline aqueous solution, but is soluble in acidic aqueous solution.Type: GrantFiled: December 30, 1996Date of Patent: August 18, 1998Assignee: Ajinomoto Co., Inc.Inventors: Toru Ikeda, Toshihide Yukawa
-
Patent number: 5783211Abstract: A stable dry powder skin care powder having prolonged and controlled release properties, useful as baby powders, body talcs, deodorizing powders, OTC eczema preparations, foot powders, anti-fungal powders, etc. The dry powder is preferably prepared by a process comprising spray-drying a mixture of liposome encapsulated active agent, starch and maltodextrin. The particle is designed so that activity of, e.g., an anti-inflammatory agent such as Dragosantol.RTM. can be specifically triggered by skin conditions, such as moisture, for optimal timing of delivery.Type: GrantFiled: November 3, 1997Date of Patent: July 21, 1998Assignee: Dragoco, Inc.Inventors: Robert P. Manzo, Jurgen Vollhardt, Nisha Malkan, Gary Friars
-
Patent number: 5783215Abstract: Controlled release beads containing a core around which is a drug-containing layer e.g. a layer containing furosemid and a process for their preparation and their use in a pharmaceutical preparation. The controlled release beads have excellent mechanical and release characteristics.Type: GrantFiled: June 22, 1995Date of Patent: July 21, 1998Assignee: Astra AktiebolagInventors: Hans Arwidsson, Lars Stubberud
-
Patent number: 5780060Abstract: Microcapsules based on crosslinked plant polyphenols are described. These microcapsules are obtained by the interfacial crosslinking of plant polyphenols, particularly flavonoids. When incorporated in a composition such as a cosmetic, pharmaceutical, dietetic or food composition, these microcapsules make it possible to prevent any impairment of this composition, in particular any color modification, while at the same time preserving the activity, especially the anti-free radical and/or antioxidizing activity, of the plant polyphenols, particularly the flavonoids.Type: GrantFiled: September 27, 1995Date of Patent: July 14, 1998Assignee: Centre National de la Recherche ScientifiqueInventors: Marie-Christine Levy, Marie-Christine Andry